Regulation of monoclonal antibody immunotherapy by FcγRIIB
Regulation of monoclonal antibody immunotherapy by FcγRIIB
Monoclonal antibodies (mAb) are revolutionising the treatment of many different diseases. Given their differing mode of action compared to most conventional chemotherapeutics and small molecule inhibitors, they possess the potential to be independent of common modes of treatment resistance and can typically be combined readily with existing treatments without dose-limiting toxicity. However, treatments with mAb rarely result in cure and so a full understanding of how these reagents work and can be optimised is key for their subsequent improvement. Here we review how an understanding of the biology of the inhibitory Fc receptor, Fc?RIIB (CD32B), is leading to the development of improved mAb treatments.
monoclonal antibody, immunotherapy, antigenic modulation, fcyriib, cd32b, immunomodulation
88-94
Stopforth, Richard J.
2d3e18ff-5563-4247-9150-f0f337fb585f
Cleary, Kirstie L.S.
5f2111f9-f570-40ce-85db-945e3930aeba
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Stopforth, Richard J.
2d3e18ff-5563-4247-9150-f0f337fb585f
Cleary, Kirstie L.S.
5f2111f9-f570-40ce-85db-945e3930aeba
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Stopforth, Richard J., Cleary, Kirstie L.S. and Cragg, Mark S.
(2016)
Regulation of monoclonal antibody immunotherapy by FcγRIIB.
Journal of Clinical Immunology, 36, Winter Issue, .
(doi:10.1007/s10875-016-0247-8).
(PMID:26922075)
Abstract
Monoclonal antibodies (mAb) are revolutionising the treatment of many different diseases. Given their differing mode of action compared to most conventional chemotherapeutics and small molecule inhibitors, they possess the potential to be independent of common modes of treatment resistance and can typically be combined readily with existing treatments without dose-limiting toxicity. However, treatments with mAb rarely result in cure and so a full understanding of how these reagents work and can be optimised is key for their subsequent improvement. Here we review how an understanding of the biology of the inhibitory Fc receptor, Fc?RIIB (CD32B), is leading to the development of improved mAb treatments.
Text
art%3A10.1007%2Fs10875-016-0247-8.pdf
- Version of Record
More information
Accepted/In Press date: 16 February 2016
e-pub ahead of print date: 27 February 2016
Keywords:
monoclonal antibody, immunotherapy, antigenic modulation, fcyriib, cd32b, immunomodulation
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 390172
URI: http://eprints.soton.ac.uk/id/eprint/390172
ISSN: 0271-9142
PURE UUID: b3fb89b6-197a-4863-a833-6c8a9f7cf10b
Catalogue record
Date deposited: 21 Mar 2016 15:29
Last modified: 15 Mar 2024 02:57
Export record
Altmetrics
Contributors
Author:
Richard J. Stopforth
Author:
Kirstie L.S. Cleary
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics